Published in Hepatitis Weekly, December 9th, 2002
The company's loss from operations was $39.6 million for the first 9 months of 2002, essentially the same as the loss from operations reported for the identical period in 2001.
Revenue for the 3 and 9 months ended September 30, 2002,totaled $20.3 million and $58.3 million, respectively, compared with $19.3 million and $31.5 million, respectively, for the same periods in 2001. The 85% increase in revenue year to date was primarily related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.